As no prophylactic application was stipulated in protocols, G-CSF was prescribed only in patients with grade 4 leukopenia; such G-CSF treatment could be one of the reasons for the increased death risk in patients with severe leukopenia. This evidence concerns the gene CSF3 and Decreased total leukocyte count.